TRT in treatment for hypogonadism and prostate cancer risk

Discussions about the pros and cons of testosterone replacement therapy (TRT) in relation to (a) stimulating risk for prostate cancer in men who have not been diagnosed and (b) recurrence of prostate cancer among men who have been diagnosed and treated often aren’t entirely clear about a very key factor. … READ MORE …

Testosterone levels in patients on androgen deprivation therapy

For the past 40 years, the formal level of “effectiveness” of androgen deprivation therapy (ADT, also known as “hormone” therapy) for men treated for high-risk, progressive, and/or metastatic prostate cancer has been a serum testosterone level of < 50 ng/dl (equivalent to < 1.7 nmol/l). However, … READ MORE …

Low serum T and active surveillance: let’s look before we leap

A new report from a group of Italian researchers has suggested that circulating serum testosterone (T) levels in the blood may be a risk for upgrading and upstaging among men initially diagnosed with low-risk prostate cancer who are managed on active surveillance. … READ MORE …

ADT, patient survival, and serum testosterone levels after initiation of treatment

Over the years there have been multiple debates about whether different types of androgen deprivation therapy (ADT) really do or don’t extend the survival of men with advanced prostate cancer of differing types and whether the degree to which ADT initially suppresses serum testosterone levels affects that survival. … READ MORE …

Efficacy of continuous ADT and correlation to nadir serum T levels

We had “missed” a poster presented at the recent meeting of the European Urology Association that appears to “put to bed” — in a positive fashion — the question of a relationship between nadir serum testosterone (T) levels in men on continuous androgen deprivation therapy (ADT) and the long-term effectiveness of continuous ADT. … READ MORE …

What is the appropriate serum T threshold for medical “castration”?

For many years, the formal threshold level of serum testosterone (T) used to define medical “castration” has been < 50 ng/dl. However, it is widely recognized that this level is probably not low enough to accurately define a medically castrate state. … READ MORE …

Baseline serum androgen levels and responses to abiraterone acetate

Baseline levels of serum androgens were predictive for clinical response to treatment in the Phase III clinical trial of abiraterone acetate in men with chemotherapy-refractory, metastatic, castration-resistant prostate cancer (mCRPC), according to a new article in the Journal of Clinical Oncology. … READ MORE …